Results 251 to 260 of about 160,978 (345)

Cardiovascular risk in cancer patients: initial experience from a cardio-oncology clinic in Mexico. [PDF]

open access: yesArch Cardiol Mex
Arroyo-Rodríguez C   +15 more
europepmc   +1 more source

Artificial Intelligence in Upper Gastrointestinal Diagnosis. [PDF]

open access: yesKorean J Helicobacter Up Gastrointest Res
Quek SXZ, Ho KY.
europepmc   +1 more source

S1‐Guideline for diagnosis and therapy of necrobiosis lipoidica

open access: yesJDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Summary Necrobiosis lipoidica (NL) is a rare granulomatous skin disease of unknown etiology that occurs frequently in association with diabetes mellitus and other comorbidities. The predilection site is the lower leg, particularly the pretibial areas. The exact pathogenesis remains unclear.
Cornelia Erfurt‐Berge   +6 more
wiley   +1 more source

Outcomes of patients with relapsed/refractory acute leukaemia treated with revumenib with a focus on post‐revumenib therapies

open access: yes
British Journal of Haematology, EarlyView.
Miles Thomas   +15 more
wiley   +1 more source

HPV42 – a human papillomavirus classified as a low‐risk type with oncogenic potential

open access: yesJDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Summary Human papillomavirus (HPV) type 42 is a rare HPV type currently classified as “low‐risk” and belongs to the alpha genus. It has primarily been detected in benign vulvar papillomas and is predominantly associated with benign lesions such as anogenital warts.
Sven Niklas Burmann   +7 more
wiley   +1 more source

Assessment of thyroid cancer risk associated with glucagon‐like peptide 1 receptor agonist use

open access: yesDiabetes, Obesity and Metabolism, EarlyView.
Abstract Aims Published literature has raised concerns regarding a causal association between glucagon‐like peptide 1 receptor agonist (GLP‐1RA) use and thyroid cancer risk in adults. In this analysis, we evaluated the association between thyroid cancer risk and GLP‐1RA use.
Tina Vilsbøll   +8 more
wiley   +1 more source

Home - About - Disclaimer - Privacy